ImmuneBiotech in the news

Press Releases

2018-06-20ImmuneBiotech and Sacco enter strategic manufacturing agreement

 

2018-05-29ImmuneBiotech´s scientifically designed probiotic product closer to the market through financial support by Vinnova

 

2018-02-15ImmuneBiotech: successful financing and strengthened management team

 

2016-05-04ImmuneBiotech AB has been awarded a grant by Innovationskontor Syd’s ACCELERATOR program

ImmuneBiotech AB has been awarded a grant by Innovationskontor Syd to support the development of a probiotic based therapy for one of the most prevalent, wide spread diseases, Irritable Bowel Syndrome (IBS).

Latest news

2018-06-27Swedish news agency Sydsvenskan (8till5): Lundabaserat inkubatorföretag tar hem kontrakt med Europadominant

 

2018-06-20Swedish news agency Rapidus newsletter 2018-06-20 : Probiotikabolag från Lund startar massproduktion

 

2018-06-07Shahram Lavasani is invited to set up and lead the following worskhop in London: Strategic competitive intelligence and the role of the Microbiome in Immuno-Oncology

 

2018-02-15Swedish news agency Sydsvenskan (8till5): Tung techprofil investerar i Lundabaserat inkubatorföretag

 

2018-02-14Swedish news agency Rapidus newsletter 2018-02-14 : ImmuneBiotech får miljontillskott från namnkunniga
investerare

 

Conferences

2018

founders-forum-meeting

Shahram Lavasani has received an exclusive invitation to attend the Founders Forum London – HealthTech 2018 and speak at the very special Biome Tech session.

June 14, 2018

 

Drug Discovery Berlin
As an honorary member of the Microbiome Director´s Club Shahram Lavasani is invited to attend the 2nd Annual Microbiome Discovery and Development Congress, Berlin, Germany.

June 7-8, 2018
1

Shahram Lavasani and Karin Larsson are attending The Microbiome Invest Congress in London, UK.

May 23, 2018

 

ImmuneBiotech has been chosen for a final Pitch:

2

 

 

3

Karin Larsson is attending the Vitafoods Europe at Palexpo, Geneva, Switzerland May 15-17, 2018.

 

 

1
Shahram Lavasani has received an exclusive invitation from Helmsley Charitable Trust and the Kenneth Rainin Foundation in New York to attend and contribute to workshop about Diet and Inflammatory Bowel Disease (IBD). New York, USA.
April 19, 2018

 

 

1
Shahram Lavasani is an invited speaker at the 18th World Vaccine Congress, section for Immune Profiling and role of the Microbiome. Washington D.C, USA.
April 4-5, 2018

 

 

1
Shahram Lavasani is an invited speaker at Microbiome Therapeutics. Amsterdam, The Netherlands.
March 14 – 15, 2018
1
Shahram Lavasani is an invited speaker at Pharmaceutical Microbiology in London, UK.
January 22–23, 2018

 

 

2017

2
Shahram Lavasani is an invited speaker at GUT-BRAIN AXIS Summit in San Francisco, USA.
December 12–14, 2017 The brochure

 

3
Shahram Lavasani is an invited speaker at Microbiome Human Nutrition Summit in Boston, USA.
November 14–16, 2017

 

4
Shahram Lavasani is an invited speaker at Pharmaceutical Microbiology East Coast 2017 in Iselin, New Jersey, USA.
November 13-14, 2017

 

5
Shahram Lavasani is an invited speaker at Medicon Valley Alliance, Microbiome Summit, Copenhagen, Sweden.
October 4-5, 2017

 

6
ImmuneBiotech is attending to the Nordic Life Science (NLS) Days in Malmö, Sweden.
September 12-14, 2017

 

immune-thumb
Shahram Lavasani is an invited speaker at Microbiome Discovery & Development Congress in Berlin, Germany
June 12-13, 2017

 

microbiom2
Shahram Lavasani is an invited speaker at Probiotics Congress and 4th Microbiome R&D and Business Collaboration Forum: Europe in Amsterdam, The Netherlands
April 3-4, 2017

 

microbiom
European Microbiome Congress, London, UK
ImmuneBiotech has been selected to PITCH YOUR MICROBES at the Congress
November 30-December 1, 2016

 

jj
JLINX Symposium, Janssen Pharmaceutica, Beerse, Belgium
October 19, 2016

 

Nordic Life Science Days in Stockholm
September 14-15, 2016

 

Southern Sweden Going Global project
2016

 

BioEurope Spring 2016
April 3-6, 2016
Stockholm, Sweden

Scientific Publications

Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells.
Nouri M, Bredberg A, Weström B, Lavasani S.
PLoS One. 2014 Sep 3;9(9)

Targeting versus tinkering: explaining why the clinic is frustrated with molecular mapping of disease mechanisms.
Bredberg A, Lavasani S.
Med Hypotheses. 2013 Oct;81(4):553-6

A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells.
Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B.
PLoS One. 2010 Feb 2;5(2)

ImmuneBiotech in the News